We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Mts Medication Technologies, | AMEX:MPP | AMEX | Ordinary Share |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.00 | - |
_________________
_________________
MTS Medication Technologies, Inc. | ||
|
||
(Exact Name of registrant as specified in its charter) |
Delaware | 001-31578 | 59-2740462 | |||
|
|
|
|||
(State or other jurisdiction | (Commission File Number) | (IRS Employer | |||
of incorporation) | Identification No.) |
2003 Gandy Boulevard North, St. Petersburg, Florida 33702 | ||
|
||
(Address of principal executive offices) (Zip Code) |
(Registrant's telephone number, including area code): (727) 576-6311
N/A | ||
|
||
(Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-42(c))
On May 2, 2008, MTS Medication Technologies, Inc. (the Company) issued a press release updating its expected revenue and earnings per diluted common share for the fiscal year ended March 31, 2008. It also announced developments related to the status of its contract regarding OnDemand machines with a customer and provided guidance regarding certain financial performance measurements for the fiscal year ending March 31, 2009. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02.
The information furnished pursuant to this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed filed for purposes of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any of the Companys filings under the Securities Act of 1934, as amended, unless otherwise expressly stated in such filing.
The information set forth under Item 2.02 of this Current Report on Form 8-K is incorporated by reference into this Item 7.01.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
Exhibit | Dexcription | |||
99.1 | Release of MTS Medication Technologies, Inc., dated May 2, 2008. |
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
MTS Medication Technologies, Inc. | |||||||||||
(Registrant) | |||||||||||
Date: May 2, 2008 | By: |
/s/ Michael P. Conroy
|
|||||||||
|
Michael P. Conroy | ||||||||||
Vice President and Chief Financial Officer |
2
1 Year Mts Medications Chart |
1 Month Mts Medications Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions